Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.6% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in CRISPR-based therapies targeting genetic diseases. The company has shown notable progress in its pipeline, particularly in addressing hereditary angioedema (HAE).

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.6% on Mar 2, 2026 15:05

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)

Healthcare sector analysts have differing opinions on Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA). Needham maintained a Buy rating for Collegium Pharmaceutical with a $54.00 price target, leading to a "Strong Buy" consensus. Conversely, William Blair issued a Hold rating for Intellia Therapeutics, resulting in a "Moderate Buy" consensus with a $16.38 price target.

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/475862/analysts-have-conflicting-sentiments-on-these-healthcare-companies-collegium-pharmaceutical-coll-and-intellia-therapeutics-ntla/

Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline

Intellia Therapeutics reported a narrower-than-expected Q4 2025 loss of 83 cents per share and total revenues of $23 million, beating analyst estimates. This performance led to a 6.4% rise in shares and follows sustained growth in collaboration revenues and strategic pipeline advancements. The company plans to fund operations into the second half of 2027, focusing on its lonvo-z candidate for hereditary angioedema with an anticipated launch in early 2027.

https://www.tradingview.com/news/zacks:b5ce94202094b:0-intellia-rises-on-q4-earnings-revenue-beat-focuses-on-pipeline/

Intellia Therapeutics (NASDAQ:NTLA) Given "Buy" Rating at Chardan Capital

Chardan Capital has reissued a "Buy" rating for Intellia Therapeutics (NASDAQ:NTLA) with a price target of $26, suggesting an 82% upside. This comes after the company reported better-than-expected Q4 results for 2025 and saw the FDA lift a clinical hold on its MAGNITUDE-2 trial. However, the company remains loss-making with negative margins, and its stock has received a consensus "Hold" rating from analysts with an average price target of $17.48.

https://www.marketbeat.com/instant-alerts/intellia-therapeutics-nasdaqntla-given-buy-rating-at-chardan-capital-2026-02-27/

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2025 Earnings Call Transcript

Intellia Therapeutics (NASDAQ: NTLA) discussed its Q4 2025 earnings and provided updates on its CRISPR gene-editing programs, lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis. The company highlighted the rapid enrollment of its Phase 3 HAELO trial for lonvo-z, with top-line data expected by mid-2026 and a BLA submission in the second half of the year. For nex-z, the clinical hold on the polyneuropathy study (MAGNITUDE-2) was lifted by the FDA, with enrollment expected to complete by year-end, while engagement with the FDA for the cardiomyopathy study (MAGNITUDE) is ongoing regarding liver enzyme elevation concerns.

https://www.insidermonkey.com/blog/intellia-therapeutics-inc-nasdaqntla-q4-2025-earnings-call-transcript-1705310/

Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones

Intellia Therapeutics Inc (NASDAQ:NTLA) announced strong Q4 2025 financial results, beating revenue estimates by approximately $10 million and reporting a narrower-than-expected loss per share. The company also confirmed key pipeline milestones for its lead hereditary angioedema (HAE) candidate, NTLA-2002, with Phase 3 data expected by mid-2026 and a U.S. launch anticipated in early 2027. This positive news led to a 4.7% surge in pre-market trading, signaling investor confidence in its financial performance and CRISPR-based therapy development.

https://www.chartmill.com/news/NTLA/Chartmill-43089-Intellia-Therapeutics-Inc-NASDAQNTLA-Reports-Strong-Q4-2025-Revenue-Beat-and-Confirms-Key-2026-Pipeline-Milestones

Trending Today

Gold ($XAU) Commodity Forecast: Down 5.2% Today

Gasoline ($GASOLINE) Commodity Forecast: Up 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.1% Today

Copper ($COPPER) Commodity Forecast: Down 4.0% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.7% Today

Estee Lauder Companies Inc. (The) ($EL) Stock Forecast: Down 4.1% Today

SoFi Technologies Inc. ($SOFI) Stock Forecast: Up 5.1% Today

Steel Dynamics Inc. ($STLD) Stock Forecast: Up 5.2% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 5.3% Today

Western Digital Corporation ($WDC) Stock Forecast: Down 5.1% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

05.01.2026 - NTLA Stock was down 6.0%

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

05.01.2026 - NTLA Stock was down 6.8%

• While the FDA lifted the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis, the stock did not respond positively.
• Despite analysts raising price targets and institutional investors expressing optimism, the stock continued its bearish movement.
• Market reaction may have been influenced by ongoing concerns about a separate clinical hold on the cardiomyopathy study, overshadowing progress in the ATTRv-PN trial.
• Conflicting price targets provided by Baird and H.C. Wainwright possibly introduced uncertainty among investors, contributing to the stock's decline.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

04.01.2026 - NTLA Stock was down 5.7%

• The FDA lifting the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) was initially seen as a positive development, but the market reacted negatively, causing a 12.6% drop in the stock price.
• Despite the regulatory hurdle being cleared, investors may be concerned about the ongoing hold on the MAGNITUDE cardiomyopathy trial, leading to uncertainty about the company's future pipeline.
• Analysts providing varied ratings and decreased price targets could also contribute to the bearish sentiment, as the market digests the implications of the FDA decision and assesses the company's overall financial health and growth prospects.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

10.01.2026 - NTLA Stock was down 5.2%

• Despite recent developments in its MAGNITUDE-2 Phase 3 trial, Intellia Therapeutics (NTLA) saw a 6.6% decline in its stock price.
• Concerns over the ongoing hold on another trial, ATTR-CM MAGNITUDE, have affected investor confidence and contributed to the stock's bearish movement.
• Analysts' decision to maintain a "Hold" rating, reduce price targets, and insider selling have further impacted the sentiment surrounding NTLA's stock.
• The company's status as currently loss-making, alongside debates on its valuation, has led to increased stock volatility and caution among investors regarding future regulatory challenges.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

03.01.2026 - NTLA Stock was down 5.1%

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.